A. Menarini Asia-Pacific Holdings Pte Ltd.
🇸🇬Singapore
Clinical Trials
5
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)
Recruiting
- Conditions
- Hypertension
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 4537
- Registration Number
- NCT06938516
- Locations
- 🇮🇩
Telogorejo Hospital, Semarang, Central Java, Indonesia
🇮🇩Bethesda Hospital, Yogyakarta, Central Java, Indonesia
🇮🇩Panti rapih Hospital, Yogyakarta, Central Java, Indonesia
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Completed
- Conditions
- Breakthrough Cancer Pain
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 143
- Registration Number
- NCT03895762
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 3250
- Registration Number
- NCT03847350
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population
Phase 1
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03633760
- Locations
- 🇨🇳
Phase I Clinical Trial Centre, Chinese University of Hong Kong, Hong Kong, Hong Kong, China
A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT02817932
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
News
No news found